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The mitogen and stress-activated protein kinase 1
regulates the rapid epigenetic tagging of dorsal
horn neurons and nocifensive behaviour
Keri K. Tochiki, Maria Maiaru´, Caspar Norris, Stephen P. Hunt, Sandrine M. Ge´ranton*
Abstract
Phosphorylation of histone H3 at serine 10 (p-H3S10) is a marker of active gene transcription. Using cognitive models of neural
plasticity, p-H3S10 was shown to be downstream of extracellular signal-regulated kinase (ERK) signalling in the hippocampus. In
this study, we show that nociceptive signalling after peripheral formalin injection increased p-H3S10 expression in the ipsilateral
dorsal horn. This increase was maximal 30 minutes after formalin injection and occurred mainly within p-ERK-positive neurons.
Spinal p-H3S10-enhanced expression was also observed in neurokinin 1 receptor (NK1R), c-Fos, and Zif268 positive neurons and
was inhibited by ablation of serotonergic descending controls. The mitogen and stress-activated protein kinase 1 (MSK1) is
downstream of ERK and can induce p-H3S10.We found that, after formalin injection, most phospho-MSK1 (p-MSK1)-positive cells
(87%6 3%) expressed p-ERK and the majority of p-H3S10-positive cells (85%6 5%) expressed p-MSK1. Inhibition of ERK activity
with the MEK inhibitor SL327 reduced formalin-induced p-ERK, p-MSK1, and p-H3S10, demonstrating that spinal p-MSK1 and
p-H3S10 were at least partly downstream of ERK signalling. Crucially, pharmacological blockade of spinal MSK1 activity with the
novel MSK1 inhibitor SB727651A inhibited formalin-induced spinal p-H3S10 and nocifensive behaviour. These findings are the first
to establish the involvement of p-H3S10 and its main kinase, MSK1, in ERK regulation of nociception. Given the general importance
of ERK signalling in pain processing, our results suggest that p-H3S10 could play a role in the response to injury.
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1. Introduction
It is well established that activation of the extracellular signal-
regulatedkinase (ERK) regulates synaptic plasticity in neural networks
throughout the central nervous system.2,14,33 Peripheral injury
activates nociceptors and promotes the rapid expression of
phospho-ERK (p-ERK) in superficial dorsal horn neurons, leading to
central sensitization and lowered nociceptive thresholds.23 Thus,
inhibition of p-ERK results in the reduction in the sensitised state.32
How ERK mediates these changes is largely unknown, but there is
evidence to suggest that potassium channels, specifically Kv4.2,
synaptic vesicle trafficking, translation factors, and cytoskeletal
proteins are modulated by ERK.28,30,33 Moreover, changes in gene
expression are known to underlie the plasticity that contributes to the
fullmanifestation of pain states37 and recent data raised thepossibility
that ERK could control gene expression through epigenetic histone
modifications.16
Epigenetic modifications of histone proteins or DNA are now
known to play an important role in the dynamic regulation of gene
expression and neural plasticity.5,56 Transcriptionally permissive
histonemodifications on histone H3, particularly phosphorylation at
serine 10 (p-H3S10) and also acetylation at lysine 14 (AcH3K14), or
a combination of these 2 marks, are upregulated in the
hippocampus in association with consolidation of fear memory
and on exposure to environmental novelty.12,26,39 The signalling
pathways that initiate these changes have not been fully identified.
However, it has been shown that ERK activity regulates memory
formation in hippocampal neurons through themitogen and stress-
activated protein kinase 1 (MSK1) and histone phosphorylation at
serine 10 (p-H3S10).13,14 Moreover, ERK/MAPK signalling is
required for the synaptic activity-induced,NMDA-mediated, nuclear
infolding seen in hippocampal neurons, a process that correlates
with phospho-MSK1 (p-MSK1) and p-H3S10 expression levels.54
Finally, genetic inactivation ofMSK1 reduces the phosphorylation of
histone H3 at serine 10 at the FosB promotor in the striatum.22
Although epigenetics studies have elucidated a role for spinal
histone acetylation and histone-acetylating enzymes in the
regulation of acute and long-term pain behaviours,3,11,20,21,25,51
injury-induced histone phosphorylation in the spinal cord has not
yet been investigated. Given the importance of ERK signalling
during the early phase of pain processing after injury,32 the
potential role of the kinase in the phosphorylation of histone H3,16
and the role of p-H3S10 in neural plasticity, we have investigated
the possibility of rapid epigenetic p-H3S10 tagging of dorsal horn
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neurons through ERK signalling after noxious stimulation, using
molecular and behavioural techniques, combined with pharma-
cological inhibition of signalling pathways.
2. Methods
All procedures were licensed under the Animals (Scientific
Procedures) Act 1986. Experiments were performed using adult
male Sprague-Dawley rats at 200 to 230 g at the beginning of the
experiments and bred by the UCL Biological Services Unit. For
experiments in which animals required intrathecal (i.t.) surgery, all
animals weighed between 170 and 185 g on the day of the i.t.
surgery. Animalswerehoused4maximumtoacage,with a12-hour
light–dark cycle (lights on beginning at 08:00) and access to food
and water provided ad libitum.
2.1. Models of acute pain
Acute inflammation was induced with an intraplantar hind paw
injection of formalin (33.3mmol or 1 mg in 50mL, 2%) or capsaicin
(25 mL, 1%) under isoflurane anaesthesia (5% for induction and
2.5% for maintenance under nose cone combined with 100%O2,
2 L/min) using a 1-mL syringe and disposable 30-G ½-inch
needle. After anaesthesia, animalswere returned to a temperature-
controlled recovery box until regaining consciousness. Sham
animals were subjected to the same anaesthesia that was used for
the injected animals but received no injection. Any injection would
indeed trigger inflammation and therefore activate nociceptive
pathways in the superficial dorsal horn, only to a different degree.
To allow for behavioural observation after formalin, a non-
anaesthetised injection was required. Because of Home Office
licence limitations, formalin injections performed without anaes-
thesia were delivered in 20 mL (33.3 mmol or 1 mg; 5%), during
which the animal was lightly restrained in a leather glove. The
survival times after treatment ranged from 5 minutes to 4 hours
depending on the experiment.
2.2. Behaviour
Formalin-induced behaviours were recorded with a Panasonic
SDR-H100 video camera for 60 minutes after formalin injection
with animals placed in an 11- 3 17-cm perspex box. Behaviour
was scored and quantified as the length of time spent licking and
flinching, or the number of total flinches in 5-minute bins across
the full 60 minutes after injection. All scoring was done with the
experimenter blind to treatment.
2.3. Drugs
Desipramine (Sigma D3900; i.p. 25 mg/kg per 0.9% saline),
a norepinephrine reuptake inhibitor, was administered 1 hour
before 5,7-dihydroxytryptamine creatinine sulphate (5,7-DHT) to
prevent toxicity to noradrenergic neurons. 5,7-DHT (Sigma 37970;
i.t. 60 mg in 10 mL/0.9% saline) was used to ablate descending
serotonergic fibres from the rostral ventromedial medulla (RVM)
and administered 7 days before formalin stimulation. SL327 (Tocris
1969; i.p. 50 mg/kg per DMSO; Tocris Bioscience, Bristol, United
Kingdom) and SB747651A (Tocris 4630; i.t. 10 mM in 10 mL or
1 mM in 10 mM per 0.0086% ethanol per 0.9% saline) were
delivered 30 minutes before formalin stimulation.
2.4. Intrathecal surgery
Surgery was performed under isoflurane anaesthesia (5% for
induction and 2.5% for maintenance under nose cone combined
with 100%O2, 2 L/min). The head of the animal was shaved, and
the animal was secured in a stereotaxic frame. After sterilisation
of the shaved area, an incision was made using a #22-blade from
the top of the head to the base of the skull/first vertebra. The
muscle was parted to reveal the atlanto-occipital membrane,
which was carefully pierced and a small opening was cleared to
allow insertion of a polyethene tube (diameter 0.28 mm) attached
to a 50 mL Hamilton syringe containing either drug or vehicle. The
tubing was carefully inserted into the subarachnoid space and
guided to a predetermined location identifying the L4/L5 spinal
cord region and 10 mL of solution delivered. The tube was
inserted without resistance, and care was taken not to damage
the spinal cord or dorsal roots. Once the tube was removed, the
overlying muscle was sutured using 5-0 Mersilk, and the wound
was subsequently closed with three 11- 3 2-mm suture clips.
The animal was then placed into a temperature-controlled
recovery box and monitored closely for signs of locomotor
impairment or distress once awake. Animals receiving 5,7-DHT
were also monitored for any weight loss after surgery for 6 days.
2.5. Perfusion and tissue collection
After formalin stimulation, animals were deeply anaesthetised first
with isoflurane and subsequently with pentobarbital (Euthatal; i.p
0.8 mL/animal). After breathing stopped and the animal failed to
exhibit eyelid reflex, a transcardial perfusion was performed first
with heparinised saline (5000 IU/L 0.9% saline) followed by 4%
paraformaldehyde (PFA)/0.1M phosphate buffer (PB) for 7
minutes, using a pump and 18-gauge cannula delivering the
fixative at 30 mL/min. The PFA solution contained 0.2% (wt/vol)
sodium fluoride (NaF), a phosphatase inhibitor. The spinal cord
was extracted and postfixed for 2.5 to 3 hours in the same PFA
solution and subsequently stored at 4˚C in 30% sucrose/0.1 M
PB/0.02% (wt/vol) azide for cryoprotection for at least 48 hours
before further processing.
2.6. Immunohistochemistry
Antibodies were detected with either fluorescent (Alexa Fluor
conjugate or tyramide signal amplification) or chromogenic (3,39
diaminobenzidine [DAB])methods. TheL4 toL6 regionof the spinal
cord was isolated for sectioning on a Leica SMR2000R freezing
microtome. Serial 40-mmcoronal sectionswere taken in 6 sets and
stored in 5% sucrose/0.1 M PB/0.02% (wt/vol) azide until
immunohistochemistry. All immunohistochemistry was done free
floating in volumes of 1 mL with gentle rocking agitation unless
otherwise stated. Three 10-minute washes in 0.1 M PB were
performed after incubationwith all solutions except after incubation
with blocking solution. Washes were done in excess of 1 mL.
In some cases, an antigen retrieval step was required (for
p-H3S10 when using a direct protocol, see below). In this case,
sections were acid-pretreated with 2 N hydrochloric acid (HCl) for
30minutes followed directly by a neutralisation step of 0.1Mboric
acid for 10 minutes before serum block. Sections were blocked
for 1 hour in 3% normal goat or horse serum (Vector Laboratories,
Peterborough, United Kingdom) depending on the host of the
secondary antibody, and 0.3% triton X-100 in 0.1 M PB to
minimise nonspecific binding of secondary antibodies. For
chromogenic staining, 2% H2O2 was added to the blocking
solution to quench endogenous peroxidase activity and minimise
background. After removal of the blocking solution, primary
antibody was added overnight (O/N) at room temperature (RT) or
over 3 days (5-HT, NK1, p-H3S10, and p-MSK1) at 4˚C in Triton-
Tris-buffered saline. Where a double stain was completed with 2
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antibodies of the same host, a negative control eliminating the
second primary confirmed no cross reactivity of secondary
antibodies. 5-HT (Chemicon/Merk Millipore, Darmstadt, Germany
MAB352; 1:75) was detected using Biotin Amplification as
previously described.24 Antibodies detected using tyramide signal
amplification as previously described51 were used as follows: c-
Fos (Calbiochem, San Diego, CA, PC38, 1:20,000), NK1R (Merk
Millipore, Darmstadt, Germany AB5060, 1:20,000), nNOS (Cell
signalling, Danvers, MA, 4231S, 1:1000), p-ERK (Thr202/Tyr204)
(Cell signalling 9101), p-H3S10 (Abcam, Cambridge, United
Kingdom, ab14955, 1:10,000), p-MSK1 (Thr581) (Cell signalling
9595, 1:500), and Zif268 (Egr-1) (Santa Cruz Biotechnology,
Dallas, TX sc-189, 1:10,000). When using a conventional DAB
protocol for detection, antibodies were used at the following
concentration: c-Fos, 1:10,000; p-ERK (Thr202/Tyr204), 1:500;
and p-H3S10 1:5000. Antibodies detected using Alexa Fluor
conjugates were NeuN (Chemicon MAB377, 1:1000); p-ERK
(Thr202/Tyr204) (1:500); p-H3S10 (1:500, O/N; HCl pretreatment
required), Iba-1 (Wako, Richmond, VA 019-19,741, 1:1000, O/N,
RT), glial fibrillary acidic protein (GFAP) (Dako, Cambridge, United
KingdomZ0334, 1:4000,O/N,RT), APCCC1 (CalbiochemOP-80,
1:100, O/N, RT).
2.7. Imaging and quantification
DAB stains were imaged using a Nikon Coolpix E4500 digital
camera attached to a Nikon Eclipse E800 microscope. Images of
fluorescent stains were captured using a Hamamatsu CCD
C4742 digital camera attached to a Leica DMRmicroscope using
Volocity software (PerkinElmer, Waltham, MA). To study coloc-
alisation, images were captured using a Leica TCS SPE Laser
scanning confocal microscope. A single focal plane was used for
any colocalisation image presented using confocal microscopy.
Immunopositive cells for all sections were counted manually
with the experimenter blind to treatment. The immunopositive
cells were separated by laminae I–II and III–V. Once all sections
were counted, per animal, 5 sections with the maximum
response (ipsilateral) were used and the average taken on the
ipsilateral and, when relevant, contralateral side of the dorsal
horn. The average of the treatment group was then calculated
along with the SE of each group mean (SEM).
If the goal was to obtain a percentage overlap of 2 labelled
populations, cells of the first population were quantified using the
above protocol. Then, in the same tissue sections, the second
population of interest, as well as the population of double-labelled
cells, was quantified. The percentage of double labelling was then
calculated for each section of tissue, and averaged per animal.
Finally, the average percentage of double labelling for the group
was presented as mean6 SEM. Because the maximal expression
of 2 populations of interest may not occur in the same tissue
sections, out of interest, themaximumpercentageoverlapwas also
calculated by selecting the5 tissue sectionswithmaximal response
from the second population. However, there was never any
difference in percentage overlap values when using 5 sections with
maximum response per animal from either combination of stain.
2.8. Statistical analysis
All statistical analyses were performed using IBM SPSS PC1
(Chicago, IL) or Microsoft Excel (Redmond, WA). Analyses were
performed using independent t tests or 2- or 3- way, if relevant
repeated-measures, analysis of variance (ANOVA), as appropriate,
followed by univariate post hoc analysis. A significant main effect of
treatment or significant interaction was a condition to follow onwith
post hoc analysis. Data were checked for normal distribution using
the Shapiro–Wilk analysis, and homogeneity of variance using the
Levene test before performing parametric analyses. Data were
checked for sphericity using the Mauchly test of sphericity and
when violated, the Greenhouse–Geisser correction was used. For
all experiments, a statistical significance level ofP,0.05wasused.
3. Results
3.1. p-H3S10 is upregulated in ipsilateral dorsal horn
neurons of the spinal cord after noxious hind paw stimulation
by formalin and capsaicin
There was a rapid increase in p-H3S10-labeled nuclei in the
medial superficial dorsal horn as early as 5 minutes after
intraplantar formalin injection (Fig. 1A, B). The number of
p-H3S10-labeled nuclei increased only on the ipsilateral side (2-
way ANOVA: differences across time points: F(4,10) 5 8.5, P ,
0.01, post hoc analysis for the ipsi side only: F(4,10) 5 7.8, P ,
0.01; ipsi vs contra: F(1,10)5 104.2, P, 0.0001). Expression of p-
H3S10 in superficial laminae I–II was maximal at the 30-minute
time point (mean, 20.5 6 3.2 cells per 40-mm section). In deeper
laminae III–V, maximum expression of p-H3S10 occurred at 1
hour (mean, 13.3 6 1.7 cells per 40-mm section; 2-way ANOVA:
differences across time points: F(4,10) 5 9.9, P , 0.01, post hoc
analysis only for the ipsi side: F(4,10)5 8.3,P, 0.01; ipsi vs contra:
F(1,10)5 49.4,P, 0.0001). By 4 hours, p-H3S10 levels were back
to baseline. We also observed the expression of p-H3S10 in the
ipsilateral superficial dorsal horn at 1 hour after intraplantar
capsaicin stimulation (10.0 6 1.0 nuclei across lamina I–II per
40-mm section, n 5 4). Previous studies have shown that
p-H3S10 occurs in neurons.18 To identify whether formalin-
induced spinal p-H3S10 was also occurring in neurons, we
performed colocalisation of p-H3S10 and the neuronal marker
NeuN. We found that formalin-induced p-H3S10 nuclei colocal-
ised almost exclusively with NeuN in the dorsal horn (Fig. 1C).
p-H3S10 was not seen to colocalise with glial cells using the
astrocytemarker,GFAP, the oligodendrocyte precursor cellsmarker
APCCC1, or Iba-1, amicrogliamarker (Figure S1 available online as
Supplemental Digital Content at http://links.lww.com/PAIN/A323).
Thus, p-H3S10 was rapidly and transiently upregulated in
neurons of the superficial dorsal horn after peripheral noxious
stimulation. We next characterised the neuronal population
expressing p-H3S10.
3.2. p-H3S10 upregulation occurs in neurons of the
pain pathways
p-ERK, c-Fos, and Zif268 have been shown to be rapidly and
transiently upregulated after peripheral stimulation.31,32,53 We
therefore investigated whether p-H3S10 could be coexpressed
with these markers. Moreover, NK1 receptor (NK1R)-positive
neurons are important for nociceptive regulation,43 and we also
looked at the coexpression of p-H3S10 and NK1R.
3.2.1. p-H3S10 is expressed in p-ERK-positive neurons
We first investigated thecolocalisation of p-H3S10nuclei andp-ERK.
Maximal expression of p-ERK occurs 5 minutes after formalin
injection,32 and levels remain elevated for at least 30 minutes. This
allowedus to assess the coexpressionof p-H3S10andp-ERKat this
time point. In laminae I–II, 51%67%of all p-H3S10-expressing cells
colabelled with p-ERK, whereas 44% 6 3% of p-ERK-expressing
cells also expressed p-H3S10 (mean p-ERK population 30.7 6 7.4
cells per 40-mmsection;mean number of double-labelled cells: 13.9
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6 3.8 per 40 mm section) (Fig. 2A). In laminae III–V, similar
percentages of colocalisation were observed: 49% 6 8% of p-
H3S10-expressing cells coexpressed p-ERK and 35% 6 6% of p-
ERK-expressing cells also coexpressed p-H3S10 (mean p-ERK
population 16.6 6 5.5 cells per 40-mm section; mean number of
double-labelled cells: 5.1 6 1.1 per 40-mm section).
3.2.2. p-H3S10 coexpression with immediate early gene
products c-Fos and Zif268
The immediate early gene (IEG) products c-Fos and Zif268 are
markers of neuronal plasticity known to have maximum expression
in the ipsilateral dorsal horn 1 to 2 hours after noxious stimulation.
Robust upregulation of both c-Fos and Zif268 was observed 1 hour
after formalin injection. Both populations had a larger and more
anatomically widespread distribution compared with that of the p-
H3S10 population (Fig. 2B, C). In lamina I–II, 61% 6 8% of p-
H3S10-positive neurons coexpressedc-Fos,whereas17%63%of
c-Fos-positive neurons coexpressed p-H3S10 (mean c-Fos pop-
ulation 35.262.3 cells per 40-mmsection;meannumber of double-
labelled cells: 6.26 1.2 per 40 mm section). Of note, 57%6 5% of
the p-H3S10 population of neurons coexpressed Zif268, whereas
12% 6 1% of the Zif268 population coexpressed p-H3S10 (mean
Zif268population 53.667.7 cells per 40-mmsection;meannumber
of double-labelled cells: 6.3 6 1.2 per 40-mm section).
3.2.3. p-H3S10 is expressed in NK1R-positive neurons
Excitatory NK1R-positive neurons are key to nociceptive process-
ing. Indeed, selective ablation of these neurons was shown to
significantly reduce injury-induced hypersensitivity.43 Analysis of p-
H3S10 colocalisation with NK1R-positive neurons at 1 hour after
formalin injection indicated that 4.5% 6 2% of laminae I and II p-
H3S10 coexpressed NK1R and in laminae III–V 4% 6 1% of p-
Figure 1. p-H3S10 rapidly increases in the ipsilateral dorsal horn after inflammation was induced through hind paw formalin injection and is expressed
predominantly in neurons. (A) Representative images of nuclear p-H3S10 distribution within the L4 dorsal horn 30 minutes after formalin injection. White lines
indicate border between gray and white matter. Lowmagnification: scale bar, 50mm. Highmagnification: scale bar, 30 mm. (B) Ipsilateral and contralateral counts
of p-H3S10 in laminae I and II and laminae III–V (n5 3 each time point, 5 sections per animal). Data showmean6 SEM (per 40mmsection). *P, 0.05; **P, 0.01;
Bonferroni post hoc analysis for comparisons across ipsi sides and paired t test for comparison ipsi vs contra. (C) p-H3S10 (green) and NeuN (red) expression in
formalin-stimulated animals. In the merge, yellow indicates colocalisation. Arrowheads indicate examples of colocalisation. Scale bar, 25 mm.
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H3S10 colabelled NK1R (Fig. 2D). These numbers were expected
considering the small NK1 population size. We also calculated that
17%6 8% of lamina I NK1R-expressing neurons coexpressed p-
H3S10 (mean NK1R population: 6.5 6 1.5 cells per 40-mm
section; mean number of double-labelled cells: 1.3 6 0.7 per 40-
mmsection) and in laminae III–V, 15%6 6%of NK1R-positive cells
coexpressed p-H3S10 (meanNK1R population 6.16 1.2 cells per
40 mm section; mean number of double-labelled cells: 0.8 6 0.4
per 40 mm section).
Our results showed that formalin-induced p-H3S10 nuclei
colocalised with p-ERK, c-Fos, Zif268, and NK1R. This sug-
gested that p-H3S10 could play an important role in nociception.
3.3. Depletion of spinal serotonin (5-HT) prevents the full
expression of formalin-induced p-H3S10
Nociceptive signalling in the superficial dorsal horn is known to be
regulated by descending controls from the brain. We therefore
investigated whether p-H3S10 expression was modulated by
descending serotonergic circuits that are known to regulate
dorsal horn activity.44
We used i.t. delivery of the neurotoxin 5,7-DHT to lesion 5-HT-
containing descending fibres from the RVM and found that 5,7-
DHT caused a specific depletion of 5-HT in the spinal cord (Fig.
3A) and a 50% reduction in p-H3S10 nuclei 30 minutes after
formalin injection compared with the vehicle (2-way ANOVA,
factor treatment F(1,24) 5 9.44, P , 0.01, side x treatment
interaction: F(1,24) 5 9.14, P , 0.01) (Fig. 3B). There were no
indication of neuronal death or gliosis as shown byNeuN or GFAP
immunostaining at 30 minutes after formalin injection in animals
depleted of spinal 5-HT (Figure S2, available online as Supple-
mental Digital Content at http://links.lww.com/PAIN/A323).
TheRVM is known to have bidirectional inhibitory and facilitatory
descending influences on spinal nociception.52 However, the
majority of studies using 5,7-DHT to lesion 5-HT-containing fibres
have concluded an overall facilitatory role for 5-HT on spinal
Figure 2.p-H3S10 expression occurs within neurons of the pain pathways. (A) Dorsal horn images of p-ERK (green) and p-H3S10 (red) double labelling in laminae I
and II. In the merge, colocalisation is seen in yellow. Scale bar, 30 mm. (B) Dorsal horn images of c-Fos (green) and p-H3S10 (red) double labeling in formalin-
stimulated animals. In the merge, colocalisation is seen in yellow. Scale bar, 50 mm. (C) Dorsal horn images of Zif268 (green) and p-H3S10 (red) double labeling. In
the merge, colocalisation is seen in yellow. Scale bar, 50 mm. (A-D) White lines indicate medial border between lamina I and white matter; arrowheads indicate
examples of colocalisation. All sections are 40 mm shown taken in a single focal plane in a formalin-stimulated animal. (D) Dorsal horn images of NK1R (green) and
p-H3S10 (red) double labeling. The final image shows a merge of the first 2 images; NK1R is a cell-surface receptor and thus colocalisation is shown as NK1R
surrounding the p-H3S10-labelled nucleus. Scale bar, 30 mm.
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nociception.24,50 Our findings here, showing that 5-HT is required
for the full expression of formalin-induced p-H3S10, would
therefore support a pronociceptive role for p-H3S10. To
characterise further the potential role of spinal histone H3
phosphorylation at S10 in nociception, we next investigated the
molecular signalling events involved in formalin-induced p-H3S10
expression.
3.4. The majority of formalin-induced p-H3S10 nuclei are
downstream of ERK signalling and colocalise with p-MSK1
Our data so far suggested that p-H3S10 was partially dependent
on ERK/MAPK signalling. The role of MEK, the upstream kinase
for p-ERK, in nocifensive formalin behaviours has already been
demonstrated.33 In particular, the MEK inhibitor SL327 has been
shown to attenuate both the first and second phase of the
formalin response.1 p-MSK1 is a well-characterised kinase
directly downstream of p-ERK which can induce p-H3S1049
(Fig. 4A). However, the role of p-MSK1 in pain processing has
never been investigated. In this study, SL327 was used as
a pharmacological tool to investigate the expression of molecular
targets downstream of ERK, specifically p-MSK1 and p-H3S10,
after noxious stimulation.
Formalin stimulation induced expression of p-ERK, p-H3S10,
and p-MSK1 in laminae I and II of the ipsilateral dorsal horn at 30
minutes (26.36 2.7, 10.46 1.5, and 11.26 1.5 cells per 40-mm
section, respectively) (Fig. 4B, C, D and E). Crucially, the great
majority (87% 6 3%) of p-MSK1 nuclei colocalised with p-ERK
(Fig. 4B, F) and 85% 6 5% of p-H3S10 nuclei coexpressed
p-MSK1 (with 59% 6 5% of the p-MSK1 population coexpress-
ing p-H3S10; Fig. 4D, F).
There was a significant effect of SL327 on the expression of
p-ERK, p-MSK1, and p-H3S10 in laminae I and II of the
ipsilateral dorsal horn (2-way ANOVA: F(1,42)5 69.4; P, 0.001;
Fig. 4B, C, D, and E). After administration of systemic SL327,
there was a 65% reduction of p-ERK (F(1,14)5 31.9, P, 0.0001)
(Fig. 4E). SL327 also caused a significant reduction (73%) in
total p-MSK1 nuclei (F(1,14) 5 23.9, P , 0.0001) (Fig. 4E), and
the majority of the remaining p-MSK1-positive nuclei (63% 6
14%) still colocalised with p-ERK. There was also a significant
reduction in double-labelled cells (p-ERK 1 p-MSK1; Fig. 4F;
F(1,6) 5 12.2; P , 0.05). After SL327 administration, we also
found a 62.5% reduction in total p-H3S10 nuclei in laminae I and
II of the ipsilateral dorsal horn (F(1,14) 5 16.4, P , 0.001) (Fig.
4E), and 46% 6 8% of the remaining p-H3S10 population still
colocalised with p-ERK after SL327 administration (Fig. 4F).
Again, there was a significant reduction in double-labelled
cells after SL327 administration: p-ERK1 p-H3S10; F(1,6) 5
138.2; P, 0.0001 and p-MSK11 p-H3S10; F(1,6)5 11.3; P,
0.05 (Fig. 4F).
All together, these results strongly suggested that the
expression of p-MSK1 and p-H3S10 in the superficial dorsal
horn was mainly downstream of ERK signalling. We next
investigated whether p-H3S10 was downstream of MSK1
signalling and whether MSK1 activity might contribute to
nociceptive processing.
3.5. Inhibition of MSK1 with SB727651A reduces formalin-
induced p-H3S10 expression and prevents the full
expression of formalin-induced nocifensive behaviour
The previous experiments indicated that the majority the
p-H3S10 population colabelled with the p-MSK1 population
(85%) and that p-MSK1 and p-H3S10 populations were of similar
size. MSK1 therefore seemed to be an ideal pharmacological
target to manipulate p-H3S10 expression.
3.5.1. Inhibition of MSK1 with SB747651A reduces
formalin-induced p-H3S10 expression
The MSK1 inhibitor, SB747651A, was delivered i.t. (1 or
10 mM, delivered in 10 mL) 30 minutes before formalin
stimulation. There was no effect of i.t. SB747651A (1 mM) on
spinal p-H3S10 expression, but treatment with i.t. SB747651A
(10 mM dose) led to a significant reduction (42%; P , 0.05,
independent Student t test) in spinal p-H3S10 1 hour after
Figure 3. Depletion of spinal serotonin prevents the full expression of formalin-induced p-H3S10. (A) Typical dorsal horn image of 5-HT and p-H3S10 staining in
animals receiving i.t. saline or i.t. (5,7-DHT), 30 minutes after formalin stimulation. Scale bar, 50 mm (upper), 30 mm (lower). (B) Counts of p-H3S10 nuclei in the
ipsilateral and contralateral dorsal horn (n 5 7 each group, 5 sections per animal). Data show group mean 6 SEM (per 40-mm section). **P , 0.01.
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formalin injection (vehicle-treated animals: 13.16 2.8 cells per
40-mm section; SB727651A-1 mM: 9.5 6 1.4 cells; and
SB727651A-10 mM: 7.6 6 1.3 cells) (Fig. 5A, B). Control
experiments showed that there was no change in the
expression of upstream p-ERK and p-MSK1 between the
vehicle and SB747651A (10 mM dose) groups 30 minutes after
formalin injection (Fig. 5B).
3.5.2. SB747651A prevents the full expression of
formalin-induced nocifensive behaviour
We finally investigated the effects of SB747651A on nocifensive
behaviour. Formalin response behaviours were scored for 1 hour
after stimulation with the vehicle, 1 or 10 mM SB747651A. As
above, the 1 mM had no effect on formalin-induced nocifensive
behaviour (Fig. 6A). However, 10mMSB747651A attenuated the
formalin response compared with the vehicle-treated group.
There was a significant main effect of treatment between 35 and
55 minutes on the time spent licking and flinching (2-way
repeated-measure ANOVA, F(2,30) 5.7, P , 0.01; post hoc
analysis vehicle vs 10 mM: F(1,25) 5 10.9, P , 0.01; Fig. 6A).
Calculation of area under the curve (AUC) indicated a 30%
reduction of time spent licking/flinching in 10 mM SB747651A-
treated animals during the second phase (15–60 minutes) of the
formalin response (P , 0.05, independent Student t test)
(Fig. 6A).
Interestingly, SB747651A significantly attenuated both the
first and second phase of the formalin response when
quantified by the total number of flinches alone (2-way
repeated-measure ANOVA, time 5-10 minutes, time 3
treatment interactions: F(2,21) 5 5.1, P , 0.05; post hoc
analysis vehicle vs 10 mM: time 3 treatment interactions F(1,16) 5
9.2, P, 0.01; time 15-60 minutes, treatment: F(2,21)5 3.8, P,
0.05; post hoc analysis vehicle vs 10mM: F(1,16)5 7.6, P, 0.05,
Fig. 6B). AUC calculation indicated a significant 37% reduction
during the second phase (15-60 minutes) in SB747651A-
treated animals (P, 0.01, independent Student t test). AUC for
the first phase formalin was however not significant as it
combined 2 time bins, 5 and 10 minutes (Fig. 6B). Finally, the
10-mM dose of SB747651A had no effect on locomotion in
naive animals, as measured in the open-field paradigm
(Fig. 6C).
Figure 4.Spinal extracellular signal-regulated kinase (ERK) regulates p-MSK1 and p-H3S10 expression after formalin injection. (A) Diagram of postulated signaling
pathways upstream of p-H3S10. (B) Dorsal horn images of p-ERK and p-MSK1 in vehicle- and MEK inhibitor SL327-treated animals 30 minutes after formalin
stimulation. (C) Dorsal horn images of p-ERK and p-H3S10 in vehicle- and MEK inhibitor SL327-treated animals 30 minutes after formalin stimulation. (D) Dorsal
horn images of p-H3S10 and p-MSK1 in vehicle- and MEK inhibitor SL327-treated animals 30 minutes after formalin stimulation. (B-D): Pictures show a single
focal plane. Final column images show amerge of the first 2 images; colocalisation is seen in yellow; arrowheads indicate examples of colocalisation. Thewhite line
indicates the medial border between lamina I and white matter. Scale bar, 50 mm. (E) Quantification of p-ERK, p-H3S10, and p-MSK1 single-labeled cells 30
minutes after formalin injection. n5 8 in each treatment group, 5 sections per animal. (F) Quantification of p-ERK, p-H3S10, and p-MSK1 double-labeled cells 30
minutes after formalin. n5 4 in each group. (E-F) Values presented as groupmean6SEM (per 40mmsection). *P, 0.05, **P, 0.01, ***P, 0.001, SL327-treated
vs vehicle-treated animals.
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4. Discussion
It is widely known that p-ERK is a marker of neural activation
after noxious stimulation and that spinal ERK regulates
nocifensive behaviour. Less is known, however, about the
molecular signalling events downstream of p-ERK that lead to
gene regulation after injury. Extracellular signal-regulated kinase
and MSK1 regulate p-H3S10 during memory formation,13,14
a process that requires cellular activity similar to that seen in
sensitised states after injury.34 In this study, we have shown for
the first time that activation of spinal MSK1 regulates the
molecular events downstream of ERK, including the phosphor-
ylation of histone H3 at serine 10, and formalin-induced
nocifensive behaviour.
4.1. Extracellular signal-regulated kinase regulation of
p-H3S10 in models of synaptic plasticity
p-ERK is a classical marker of primary afferent nociceptive
activation and central sensitisation.23 p-H3S10 is known to
occur downstream of ERK through MSK1,49 and strong
coupling of p-ERK and p-H3S10 has been confirmed in
various models of activity-induced synaptic plasticity in the
brain.7,14,16,18 One hour after pharmacological activation of
neuronal activity with kainic acid, 80% of p-H3S10 nuclei
colocalised with p-ERK in neurons of the dentate gyrus.18
Furthermore, p-H3S10 was found to be highly coexpressed
(94%) with p-ERK in the lateral septum of the brain 1 hour after
plasticity induced by naloxone-precipitated morphine with-
drawal.15 Our results, showing that more than half of the
spinal p-H3S10 population overlapped with p-ERK 30
minutes after formalin, suggested that p-H3S10 could also
be downstream of p-ERK signalling in the superficial dorsal
horn.
Pharmacological blockade of ERK signalling with the MEK
inhibitor SL327 was a crucial experiment to investigate the
contribution of ERK signalling on p-MSK1 and p-H3S10
expression. The reduction in both formalin-induced p-MSK1
and p-H3S10 after SL327, by 73% and 62.5%, respectively,
indicated a strong requirement of ERK signalling for the
full expression of p-MSK1 and p-H3S10, as previously
shown.7,9,10,14,15,45 It is important to note that p-ERK, p-MSK1,
and p-H3S10 peak at different time points, and therefore the
percentages of exact overlap are most probably greater than
those suggested here. To conclusively establish that p-H3S10 is
entirely downstream of p-ERK would require the complete
elimination of p-ERK—a condition that was not fulfilled with 50
mg/kg SL327, a dose previously used by others.1 Therefore,
whether an ERK-independent signalling cascade could induce
spinal p-H3S10 remains to be explored.
4.2. Targeting p-H3S10 through MSK1
MSK1 was an ideal target for interfering with p-H3S10 because it
is upstream of p-H3S10 and 85%of S10 nuclei also expressed p-
MSK1. It should be noted that another kinase, p70 ribosomal s6
kinase (RSK2), that lies downstream of ERK, might also activate
p-H3S10.16 Moreover, MSK1 had never been explored within the
context of nociception, despite being a direct downstream target
of ERK. The induction of p-MSK1 observed at 30 minutes after
stimulation was in agreement with a previous study that showed
neuronal induction of p-MSK1 after 15 to 30minutes of glutamate
stimulation in vitro.6
Many studies have used genetically modifiedmice to show that
MSK1 regulates neural plasticity, in particular memory forma-
tion.8,9,13,17,35 MSK1 has also been shown to modulate dendritic
morphology and synaptic plasticity involved in hippocampal
environmental enrichment and homeostatic synaptic scaling.
This is believed to happen by CREB-mediated regulation of
AMPA subunit GluR1 expression, through the IEG arc/arg3.1,
which is upregulated in the spinal dorsal horn by noxious
stimulation.17,29
Recently, a new inhibitor with improved selectivity for
MSK1, SB747651A, has become available (Tocris, Bristol,
United Kingdom).42 There were no upstream changes in ERK
activation after administration of SB747651A, supporting the
targeted specificity of MSK1 inhibition. There were also no
changes in p-MSK1 expression. This was expected as
SB747651A is a specific inhibitor of the MSK1 N-terminal
kinase, the domain reportedly essential for the phosphoryla-
tion of downstream MSK1 substrates.40 The antibody used to
detect p-MSK1 was specific to phosphorylation at
threonine 581 in the C-terminal kinase domain, activity that
precedes N-terminal activity. SB747651A reduced formalin-
induced p-H3S10 by 50%, confirming that p-H3S10 was
Figure 5. Inhibition of MSK1 with SB747651A (10 mM) causes a reduction in formalin-induced p-H3S10 but has no effect on p-ERK and p-MSK1 expression.
(A) Images of spinal p-H3S10 in vehicle- and SB747651A (10 mM)-treated animals, 1 hour after formalin injection. Scale bar, 100 mm; the white line indicates the
medial border of lamina I and white matter. (B) Quantification of p-H3S10, p-ERK, and p-MSK1 in the dorsal horn of the vehicle or SB747651A (10 mM) formalin-
treated animals (n 5 8 in each group, 5 sections per animal). Values presented as group mean 6 SEM (per 40 mm section).
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downstream of p-MSK1 signalling. SB747651A also reduced
formalin-induced nocifensive behaviour, revealing for the first
time the role of MSK1 in nociceptive processing.
4.3. Inhibition of MSK1 reduces formalin-induced
nocifensive behaviour
Many studies have investigated the effect of ERK inhibition on
formalin-induced nocifensive behaviour. Extracellular signal-
regulated kinase is often targeted by inhibition of its upstream
kinase, MEK, using inhibitors such as PD98059 and U0126.
Regardless of the behaviour observed (ie, time licking/lifting or
number of flinches), all studies have reported a reduction of
nocifensive behaviour after MEK inhibition in the second phase
of the formalin test.32,38,50,55 Although the extent of the
inhibition differs widely across studies, a 30% to 80% decrease
is usually reported. In this study, we found that MSK1 inhibition
with SB747651A inhibited nocifensive behaviours in the
second phase of the test by 30% to 50%, which would
suggest that MSK1 signalling is one of the main signalling
pathways downstream of ERK that contributes to sensitised
states.
We also observed a reduction in the number of flinches in the
first phase of the formalin test, and it has been argued that, in
rats, flinches could be a better reflection of nociceptive
responses than licking.4,41 This would suggest that
SB747651A indeed reduces nociceptive behaviour in the first
phase of the formalin response. It should be noted that the
reduction in flinching, measured in numbers, could not be seen
when time spent licking and flinching was plotted because the
time spent licking was much greater than the time spent
flinching. Moreover, although there are no reports of a reduction
of the nocifensive behaviours in the first phase of the formalin
test, most studies using MEK inhibitors show a trend for
a decrease at a specific early time point, and this trend is often
lost when the first phase is analysed as a longer time bin, as seen
in our study. Finally, it should be mentioned that although we
ascribed the molecular and behavioural effects of SB747651A
and the MEK inhibitor SL327 to the modulation of the ERK and
MSK1 signalling pathways, there is a possibility that these
observations could also be partially attributed to off-target
effects.
4.4. p-H3S10 regulation of specific gene programmes
Evidence from previous studies of learning and memory suggest
that ERK-dependent MSK1 actively contributes to the regulation
of gene expression through direct manipulation of p-H3S10.
Because of the partial overlap between p-H3S10 and other
nociceptive markers, such as c-Fos and Zif268, it is highly likely
that the consequences of histone H3 phosphorylation at S10
impact on a number of gene programs in various subsets of cells.
Although the downstream targets through which p-ERK contrib-
utes to sensitised states remain largely unknown, the results of
our study suggest that this could occur through upregulation of
the CREB-GluR1 pathway that has been shown to be modulated
by MSK1.17,29 Moreover, a number of genes under the regulation
of the transcription factor CREB could also be under the
regulation of p-H3S10. As the general function of p-H3S10 is to
aid in the relaxation of chromatin, it is possible that p-H3S10 and
CREB (both through phosphorylation by MSK1) could act
together to permit transcription.
Candidate genes under the regulation of p-H3S10 activity are
likely to be plasticity related and, indeed, p-H3S10 has been
shown to be directly responsible for the induction of the IEGs
c-Fos and Zif268 in granule neurons of the dentate gyrus.27
Virtually all of p-H3S10 neuronal nuclei have been shown to
coexpress c-Fos mRNA, with PH3S010 expression always
Figure 6. SB747651A (10 mM) attenuates nocifensive behaviour but does not
impair motor function. (A) SB747651A (10 mM) attenuated the time spent licking
and flinching during the second phase of the formalin response (35-60 minutes
after formalin injection). AUC comparison indicated a 30% reduction of time
spent licking/flinching in SB747651A (10mM)-treated animals during the second
phase (15-60 minutes) of the formalin response. N5 11 to 16. (B) SB747651A
(10mM)also reduced the formalin-inducednumberof flinchesduring the first and
second phases of the formalin response. AUC comparison indicated a 43%
reduction of flinch behaviour during the first phase (0-10 minutes) and 37%
reduction during the second phase (15-60 minutes) in SB747651A (10 mM)-
treated animals. N5 8 to 10. (C) There were no differences in the total distance
travelled in the open-field paradigm between vehicle- and SB747651A (10 mM)-
treated naive animals. (n 5 3/4 in each group). (A-C). Mean 6 SE mean. *P ,
0.05, **P , 0.01; ***P , 0.001 between vehicle and 10 mM SB747651A.
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preceding that of c-Fos in the dentate gyrus.18 Our data indicated
that at least 61% of p-H3S10 expressed c-Fos 1 hour after
formalin injection and that the percentage overlap of p-H3S10/p-
ERK occurred at around 50%. This suggested that at least 10%of
the p-H3S10 population expressed both p-ERK and c-Fos,
indicating a potential ERK-dependent regulation of c-Fos through
p-H3S10. Others have shown that spinal ERK has significant
regulation over c-Fos expression after nociceptive activation36
and that ERK controlled c-Fos expression in a p-MSK1- and
p-H3S10-dependent mechanism in models of addiction.7,46
However, the fact that in our study only 17% of c-Fos-positive
neurons coexpressed p-H3S10 also suggests that other routes
contribute to c-Fos activation. The IEG Zif268 is also known to
regulate nociceptive processing,47 and our results indicated that
57%of p-H3S10 expressed Zif268. Experiments usingChIP have
shown that upregulation of Zif268 occurs in the brain under the
regulation of p-H3S10 during cognitive processing,26 and ERK
regulation of Zif268 has been well established in striatal and
dentate gyrus neurons exhibiting LTP.19,48 However, less is
known about ERK regulation of Zif268 in the spinal cord.
In conclusion, our study is the first to elucidate the phosphor-
ylation of MSK1 in the superficial dorsal horn as amolecular event
downstream of ERK signalling that contributes to the full
expression of pain states. Moreover, we report that dorsal horn
neurons are rapidly epigenetically tagged with p-H3S10 after
peripheral noxious stimulation and that this occurs downstream
of MSK1 and ERK signalling. These results strongly suggest that
p-H3S10 could regulate spinal nocispecific gene programmes
after peripheral injury.
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